We are live on ! Find out more
VM

VHCP Management Portfolio holdings

AUM $93M
1-Year Est. Return 10.04%
This Fund
S&P 500
This Quarter Est. Return
+24.4%
1 Year Est. Return
-10.04%
3 Year Est. Return
+233.99%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$434M
AUM Growth
+$70.8M
Cap. Flow
+$15M
Cap. Flow %
3.45%
Top 10 Hldgs %
86.36%
Holding
22
New
2
Increased
2
Reduced
–
Closed
3

Top Buys

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$14.8M
2
ARCT icon
Arcturus Therapeutics
ARCT
+$9.43M
3
STML
Stemline Therapeutics, Inc.
STML
+$1.45M

Top Sells

Rank Stock Value
1
RDUS
Radius Health, Inc.
RDUS
+$9.08M
2
NBSE
NeuBase Therapeutics, Inc. Common Stock
NBSE
+$3.98M
3
VIRX
Viracta Therapeutics, Inc. Common Stock
VIRX
+$1.37M

Sector Composition

Rank Sector Weight
1 Healthcare 71.49%
2 Miscellaneous 28.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JUNO
1
DELISTED
Juno Therapeutics, Inc.
JUNO
$97M 22.32%
1,749,999
– –
ANAC
2
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$68.2M 15.7%
1,178,474
– –
ADVM
3
DELISTED
Adverum Biotechnologies
ADVM
$56M 12.9%
138,274
– –
GWPH
4
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$28.4M 6.54%
311,853
– –
CHRS icon
5
Coherus Oncology
CHRS
$226M
$26M 5.99%
870,269
– –
LRMR icon
6
Larimar Therapeutics
LRMR
$421M
$21.4M 4.94%
45,123
– –
DYAX
7
DELISTED
DYAX CORPORATION
DYAX
$16.8M 3.86%
1,000,659
– –
HRTX icon
8
Heron Therapeutics
HRTX
$63M
$15.9M 3.67%
1,095,734
– –
BCRX icon
9
BioCryst Pharmaceuticals
BCRX
$2.52B
$15.8M 3.63%
1,744,356
– –
ASND icon
10
Ascendis Pharma A/S
ASND
$16.4B
$12.9M 2.97%
+811,152
New +$14.8M
AVDL
11
DELISTED
Avadel Pharmaceuticals
AVDL
$8.99M 2.07%
500,000
– –
ARCT icon
12
Arcturus Therapeutics
ARCT
$460M
$8.45M 1.94%
+214,286
New +$9.43M
STML
13
DELISTED
Stemline Therapeutics, Inc.
STML
$6.53M 1.5%
451,400
+95,000
+27% +$1.45M
TXMD icon
14
TherapeuticsMD
TXMD
$25.7M
$5.12M 1.18%
16,930
– –
LPCN icon
15
Lipocine
LPCN
$18.4M
$4.62M 1.06%
39,407
– –
ZSPH
16
DELISTED
ZS PHARMA INC COMS TK (DE)
ZSPH
$4.21M 0.97%
100,000
– –
OCRX
17
DELISTED
Ocera Therapeutics, Inc.
OCRX
$3.31M 0.76%
703,730
– –
VIRX
18
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
– –
-2,553
Closed -$1.37M
NBSE
19
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
– –
-1,193
Closed -$3.98M
RDUS
20
DELISTED
Radius Health, Inc.
RDUS
– –
-233,294
Closed -$9.08M

Similar funds

QGI
Quadrangle GP Investors New York $93.6M AUM 10.64% 1-Year Est. Return
KC
Kanha Capital New York $89.9M AUM
RSCM
Rail-Splitter Capital Management Chicago, Illinois $89.4M AUM 15.13% 1-Year Est. Return
ZC
Zelman Capital Beachwood, Ohio $81.9M AUM 22.32% 1-Year Est. Return
TF
Trutina Financial Bellevue, Washington $76.7M AUM 19.34% 1-Year Est. Return
SAM
Sunnymeath Asset Management Red Bank, New Jersey $71.2M AUM 26.57% 1-Year Est. Return
NA
NS Advisors Westport, Connecticut $71M AUM 25.21% 1-Year Est. Return
NCIM
New Century Investment Management Southfield, Michigan $70.5M AUM 23.2% 1-Year Est. Return

VHCP Management's Q1 2015 Portfolio in Review

As of Q1 2015, VHCP Management held 22 positions worth $434M, up 19% from $364M the previous quarter. Its ten largest holdings account for 86% of the portfolio.

VHCP Management deployed $15M of net new capital in Q1 2015, opening 2 new positions and adding to 2 existing holdings. Its largest new stake was Ascendis Pharma A/S: 811,152 shares worth $12.9M.

By sector, the portfolio is most concentrated in Healthcare at 71% of assets, down from 75% a quarter earlier, followed by Miscellaneous.

On the sell side, the most notable exit was Radius Health, Inc., an estimated $9.08M sold.

  • VHCP Management's largest Q1 2015 buy was Ascendis Pharma A/S: 811,152 shares worth $12.9M.
  • VHCP Management added most to Stemline Therapeutics, Inc. in Q1 2015, an estimated $1.45M increase.
  • VHCP Management fully exited Radius Health, Inc. in Q1 2015, selling an estimated $9.08M.
  • VHCP Management's ten largest holdings make up 86% of its $434M portfolio in Q1 2015.
  • VHCP Management opened 2 new positions and closed 3 in Q1 2015.
  • VHCP Management's portfolio value rose 19% quarter-over-quarter to $434M.

Based on VHCP Management's 13F filing for Q1 2015, filed 14 May 2015.